Back to results

Active, not recruitingPhase 1

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

NCT04556773

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Commack, New York, United States

+36 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2020-12-17
Enrollment: 138 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (37)

Research SiteCommack, New York, United States
Research SiteHarrison, New York, United States
Research SiteNew York, New York, United States
Research SiteNew York, New York, United States
Research SiteUniondale, New York, United States
Research SiteChapel Hill, North Carolina, United States
Research SiteChattanooga, Tennessee, United States
Research SiteGermantown, Tennessee, United States
Research SiteFort Worth, Texas, United States
Research SiteEast Melbourne, Australia
Research SiteWestmead, Australia
Research SiteEdegem, Belgium
Research SiteLeuven, Belgium
Research SiteOttignies, Belgium
Research SiteGoiânia, Brazil
Research SitePorto Alegre, Brazil
Research SitePorto Alegre, Brazil
Research SiteSão Paulo, Brazil
Research SiteSão Paulo, Brazil
Research SiteKelowna, British Columbia, Canada
Research SiteQuébec, Quebec, Canada
Research SiteVillejuif, France
Research SiteMonterrey, Mexico
Research SiteMoscow, Russia
Research SiteMoscow, Russia
Research SiteSaint Petersburg, Russia
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteKaohsiung City, Taiwan
Research SiteTaichung, Taiwan
Research SiteTaipei, Taiwan
Research SiteTaipei, Taiwan
Research SiteTaipei, Taiwan
Research SiteTaipei, Taiwan
Research SiteTaoyuan, Taiwan

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer — TrialFind